Fig. 3From: A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinomaKaplan–Meier analysis of overall survival according to MSKCC risk scores. Overall survival was significantly greater in patients with favorable or intermediate risk scores (solid line) or a poor risk score (dotted line) (hazard ratio, 4.07; 95 % confidence interval, 1.84–9.01; P = 0.001)Back to article page